Literature DB >> 25705315

More indications approved and safety news for dabigatran etexilate.

Mircea Cinteza1.   

Abstract

Entities:  

Year:  2014        PMID： 25705315      PMCID： PMC4316890     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN： 1841-9038


× No keyword cloud information.
  12 in total

Review 1.  Dabigatran etexilate: a new oral thrombin inhibitor.

Authors:  Graeme J Hankey; John W Eikelboom
Journal:  Circulation       Date:  2011-04-05       Impact factor: 29.690

2.  Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

Authors:  Stefan H Hohnloser; Jonas Oldgren; Sean Yang; Lars Wallentin; Michael Ezekowitz; Paul Reilly; John Eikelboom; Martina Brueckmann; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2012-01-03       Impact factor: 29.690

3.  Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Authors:  Bengt I Eriksson; Ola E Dahl; Michael H Huo; Andreas A Kurth; Stefan Hantel; Karin Hermansson; Janet M Schnee; Richard J Friedman
Journal:  Thromb Haemost       Date:  2011-01-12       Impact factor: 5.249

4.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors:  B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

5.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Sebastian Schellong; Henry Eriksson; David Baanstra; Anne Mathilde Kvamme; Jeffrey Friedman; Patrick Mismetti; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

6.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

7.  A specific antidote for dabigatran: functional and structural characterization.

Authors:  Felix Schiele; Joanne van Ryn; Keith Canada; Corey Newsome; Eliud Sepulveda; John Park; Herbert Nar; Tobias Litzenburger
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

8.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

9.  The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Authors:  Stuart J Connolly; Lars Wallentin; Michael D Ezekowitz; John Eikelboom; Jonas Oldgren; Paul A Reilly; Martina Brueckmann; Janice Pogue; Marco Alings; John V Amerena; Alvaro Avezum; Iris Baumgartner; Andrzej J Budaj; Jyh-Hong Chen; Antonio L Dans; Harald Darius; Giuseppe Di Pasquale; Jorge Ferreira; Greg C Flaker; Marcus D Flather; Maria Grazia Franzosi; Sergey P Golitsyn; David A Halon; Hein Heidbuchel; Stefan H Hohnloser; Kurt Huber; Petr Jansky; Gabriel Kamensky; Matyas Keltai; Sung Soon Kim; Chu-Pak Lau; Jean-Yves Le Heuzey; Basil S Lewis; Lisheng Liu; John Nanas; Razali Omar; Prem Pais; Knud E Pedersen; Leopoldo S Piegas; Dimitar Raev; Pal J Smith; Mario Talajic; Ru San Tan; Supachai Tanomsup; Lauri Toivonen; Dragos Vinereanu; Denis Xavier; Jun Zhu; Susan Q Wang; Christine O Duffy; Ellison Themeles; Salim Yusuf
Journal:  Circulation       Date:  2013-06-14       Impact factor: 29.690

10.  Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Authors:  Sam Schulman; Ajay K Kakkar; Samuel Z Goldhaber; Sebastian Schellong; Henry Eriksson; Patrick Mismetti; Anita Vedel Christiansen; Jeffrey Friedman; Florence Le Maulf; Nuala Peter; Clive Kearon
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.